FDA reaches vague conclusion in debate over safety of paclitaxel devices - Cardiovascular Business

FDA reaches vague conclusion in debate over safety of paclitaxel devices  Cardiovascular Business

Two days of debate over the safety of paclitaxel-coated and -eluting devices have culminated in a nonbinding recommendation by the FDA to continue sales of ...



Comments

Post a Comment

Popular posts from this blog

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease - Vascular Disease Management

Orchestra BioMed™ Announces FDA Breakthrough Device Designation for Virtue® Sirolimus-Eluting Balloon for Treatment of Below-the-Knee Peripheral Artery Disease    Vascular Disease Management First and only non-coated sirolimus-eluting angioplasty balloon system to receive Breakthrough Device designation for below-the-knee disease; Follows ...
Read more